Eye-tracking women’s preferences for men’s somatotypes

Judging physical attractiveness involves sight, touch, sound and smells. Where visual judgments are concerned, attentional processes may have evolved to prioritize sex-typical traits that reflect cues signaling direct or indirect (i.e. genetic) benefits. Behavioral techniques that measure response times or eye movements provide a powerful test of this assumption by directly assessing how attractiveness influences the deployment of attention. We used eye-tracking to characterize women’s visual attention to men’s back-posed bodies, which varied in overall fat and muscle distribution, while they judged the potential of each model for a short- or long-term relationship. We hypothesized that when judging male bodily attractiveness women would focus more on the upper body musculature of all somatotypes, as it is a signal of metabolic health, immunocompetence and underlying endocrine function. Results showed that mesomorphs (muscular men) received the highest attractiveness ratings, followed by ectomorphs (lean men) and endomorphs (heavily-set men). For eye movements, attention was evenly distributed to the upper and lower back of both ectomorphs and mesomorphs. In contrast, for endomorphs the lower back, including the waist, captured more attention over the viewing period. These patterns in visual attention were evident in the first second of viewing, suggesting that body composition is identified early in viewing and guides attention to body regions that provide salient biological information during judgments of men’s bodily attractiveness.     

Molecular pharming’s foot in the FDA’s door: Protalix’s trailblazing story

Objectives

This short commentary examines the factors that led to Food and Drug Administration’s approval of the first plant-derived biologic.

Results

In 2012, the first plant-derived protein pharmaceutical (biologic) was approved for commercial use in humans. The product, a recombinant form of human β-glucocerebrosidase marketed as ELELYSO, was developed by Protalix Biotherapeutics (Carmiel, Israel). The foresight to select this particular therapeutic product for development, flawless production pipeline, and serendipity seem to provide the key in explaining how ELELYSO became the first plant-derived biologic to achieve approval by Food and Drug Administration.

Conclusions

While the circumstances that enabled Protalix and its scientists to become the first to arrive at this historic milestone are perhaps unique, it is anticipated that more biologics will follow suit in winning regulatory endorsement.

     

Africa’s highest mountain harbours Africa’s tallest trees

While world records of tree heights were set by American, Australian and Asian tree species, Africa seemed to play no role here. In our study we show that Entandrophragma excelsum (Meliaceae) found in a remote valley at Kilimanjaro has to be included in the list of the world’s superlative trees. Estimating tree age from growth rates monitored by high resolution dendrometry indicates that tall individuals may reach more than 470 years of age. A unique combination of anatomical peculiarities and favorable site conditions might explain their enormous size. The late date of this discovery of Africa’s tallest trees may be due to the comparably low study efforts at Kilimanjaro compared with other biodiversity hotspots. Since only a few square kilometers of this habitat of Entandrophragma are left, Kilimanjaro (and Africa) is about to lose not only a unique biogeographical archive with highly diverse vegetation, but also its tallest trees. The inclusion of these valleys into the immediately neighboring Kilimanjaro National Park would be an excellent and urgent possibility of protection.     

Thudichum’s Successors

This paper describes the work of five scientists who, among others, carried on the work of J. L. W. Thudichum, the pre-eminent investigator of brain chemistry in the latter half of the 19th century, after his death in 1901. This paper is dedicated to my friend Moussa Ben-Hur Youdim, who spent three years (1963–1966) in my laboratory, as a graduate student in the Department of Biochemistry, McGill University. During this time, Moussa purified monoamine oxidase of rat liver, and provided the first evidence of its multiplicity. He also contributed to the recognition of iron and riboflavin as constituents of the enzyme.     

When there’s smoke there’s.....CCN2

There is no treatment for fibrotic disease is a significant cause of mortality. CCN2 Members of the CCN family of matricellular proteins have a characteristic four domain structure. CCN2 (connective tissue growth factor) is believed to play an essential role in fibrogenesis. In a recent paper, data are provided that CCN5 (wisp2), which lacks the carboxy-terminal heparin-binding domain shared by the other CCN proteins, may act as a dominant-negative protein to suppress CCN2-mediated fibrogenesis. These data are consistent with the notion that different CCN proteins may enhance or suppress each other’s action and also suggest that CCN5, may be used as a novel anti-fibrotic therapy.